Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803711 · ClinicalTrials.gov registry record · Phase 2
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
A Phase 2 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01803711 is a Phase 2 study that was terminated before completion, run by UConn Health. The registered enrollment target is 6 participants.
The verdict
NCT01803711, a Phase 2 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).
Interventions
- DRUG Desvenlafaxine
- DIETARY_SUPPLEMENT Omega 3 Fatty acids
- DRUG Placebo (for Omega 3 fatty acid supplement)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01803711
The ClinicalTrials.gov registry entry for NCT01803711 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Desvenlafaxine is the first listed.
NCT01803711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01803711 about?
NCT01803711 is a clinical study titled "Omega 3 FA Supplements as Augmentation in the Treatment of Depression". To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).
What is the current status of trial NCT01803711?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2013-02. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01803711?
The interventions under investigation include: Desvenlafaxine (DRUG), Omega 3 Fatty acids (DIETARY_SUPPLEMENT), Placebo (for Omega 3 fatty acid supplement) (DRUG).
Who is sponsoring clinical trial NCT01803711?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.